This comprehensive comparative analysis examined the economic and health care resource utilization implications of initiating glucocorticoid and exon-skipping therapy for Duchenne muscular dystrophy ...

A mother's persistence helps revive an all-but-abandoned drug class and could aid her son and thousands of others with ...

Wave Life Sciences Ltd. plans to file with the U.S. FDA for accelerated approval of WVE-N531, an exon skipping oligonucleotide for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon ...

When your child has Duchenne muscular dystrophy, there's no way to cure it. But there are medications to help with different parts of the disease. Because of these medicines, people with DMD are ...

CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, ...

Eight therapies are approved for Duchenne muscular dystrophy (DMD) in the U.S., and all have been approved since 2016. "It took 30 years from the discovery of the gene associated with Duchenne ...

Sarepta Therapeutics has completed the submission of the casimersen (SRP-4045) NDA for the treatment of Duchenne muscular dystrophy in patients who have genetic mutations that are amenable to skipping ...

-- AMONDYS 45 is Sarepta’s third RNA exon-skipping treatment for DMD approved in the U.S.---- Commercial distribution of AMONDYS 45 in the U.S. will commence immediately ---- Information for patients ...

The beginning to the year has been eventful in the Duchenne muscular dystrophy (DMD) space, with several trial readouts announced at the Muscular Dystrophy Association (MDA) 2025 meeting, which took ...

Oxford, United Kingdom & Bothell, WA, USA — October 20, 2009 — An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and ...